Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression
September 18, 2023 07:30 ET
|
Reunion Neuroscience Inc.
WILMINGTON, Del., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for...
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
August 01, 2023 09:03 ET
|
Reunion Neuroscience Inc.
TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement
July 14, 2023 16:05 ET
|
Reunion Neuroscience Inc.
TORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement
July 13, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
June 29, 2023 07:30 ET
|
Reunion Neuroscience Inc.
Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12 Presented Encouraging Phase...
Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact
June 01, 2023 07:30 ET
|
Reunion Neuroscience Inc.
Reunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price Reunion Presents Encouraging Phase 1 Final...
Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference
April 25, 2023 07:35 ET
|
Reunion Neuroscience Inc.
TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
April 25, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors
April 03, 2023 07:30 ET
|
Reunion Neuroscience Inc.
- Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and...
Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting
March 27, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, March 27, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...